The global Anterior Uveitis Treatment Market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.
According
to a 2017 article by Retina Today, this condition accounted for around 30% to
90% of the cases of uveitis. It also stated around 1% to 4% of patients
experience 25% loss of visual acuity. There are different effective treatments
for this disease and can be easily managed; however, it tends to recur. This
disease is prevalent among both young and middle-aged group. It is also common
among the geriatric population. Ocular ischemia and herpetic uveitis are the
two most common causes of this disease among the geriatric population. Most of
the cases occur in healthy people, however, some are associated with infectious
diseases, gastrointestinal disorders, rheumatologic diseases, and lung &
skin diseases. This disease is less sight-threatening as compared to posterior
uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid
macular edema.
List Of Key Players Anterior Uveitis Treatment Market
- Novartis AG
- Santen
Pharmaceutical Co., Ltd.
- AbbVie Inc.
- Kiora
Pharmaceuticals, Inc.
- Clearside
Biomedical
- Aldeyra
Therapeutics, Inc.
- Aciont Inc.
- Sirion
Therapeutics, Inc.
- UCB S.A.
- Lux
Biosciences, Inc.
- Tarsier
Pharma Ltd.
Request a
free sample copy or view report summary: Anterior Uveitis Treatment Market Report
Anterior Uveitis Treatment Market Report Highlights
- Corticosteroids
dominated the anterior uveitis treatment market in 2023 owing to its
beneficial characteristic of minimizing inflammation in the eye. It is the
primary treatment modality.
- Anti-TNF
agents are expected to exhibit lucrative growth rate over the forecast
period due to growing opportunity in treatment methods with biologic
therapy using Anti-TNF drugs.
- Immunosuppressants
held a significant market share in 2023 owing to their growing adoption
for treatment of chronic anterior uveitis.
- Hospital
pharmacies dominated the market in 2023 due to the wide treatment options
available there.
- Online
pharmacies are expected to witness significant CAGR over the forecast
period due to convenience, ease, and availability of discounted products.
- North
America held the largest revenue share in 2023 owing to high prevalence as
well as healthcare expenditure in this region.
- Asia Pacific
is anticipated to exhibit lucrative growth during the forecast period due
to the rising number of infectious diseases in developing countries of the
region and growing disposable income.
Anterior Uveitis Treatment Market
Report Scope
|
Report Attribute |
Details |
|
Market size value in 2024 |
USD 474.0 million |
|
Revenue forecast in 2030 |
USD 967.5 million |
|
Growth Rate |
CAGR of 12.6% from 2024 to 2030 |
|
Base year for estimation |
2023 |
|
Historical data |
2018 - 2022 |
|
Forecast period |
2024 - 2030 |
Related Press Release@ Anterior
Uveitis Treatment Industry Analysis
Anterior Uveitis Treatment Market Segmentation
Grand
View Research has segmented the global anterior uveitis treatment market based
on type, therapy, distribution channel, and region:
Anterior Uveitis Treatment Type Outlook (Revenue,
USD Million, 2018 - 2030)
- Infectious
Uveitis
- Non-Infectious
Uveitis
- Anterior Uveitis
- Pan-Uveitis
- Posterior
Uveitis
- Intermediate
Uveitis
Anterior Uveitis Treatment Therapy Outlook (Revenue,
USD Million, 2018 - 2030)
- Corticosteroids
- Immunosuppressive
therapies
- Biologics
- Others
- Pipeline
Therapies
Anterior Uveitis Treatment Distribution Channel
(Revenue, USD Million, 2018 - 2030)
- Hospital
Pharmacies
- Retail
Pharmacies
- Online
Pharmacies
Anterior Uveitis Treatment Regional Outlook
(Revenue, USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin
America
- Brazil
- Argentina
- Middle East
and Africa (MEA)
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment